BCAX
Bicara Therapeutics Inc. Common Stock$19.91+0.59 (+3.06%)Prev Close$19.29·MCap$1.26B·P/E—·Vol306.4K·Yield—
▲
Buys (12M)
1
$4.80M
▼
Sells (12M)
34
$9.07M
◆
Net Activity
Net Seller
$4.27M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at Bicara Therapeutics Inc. Common Stock (BCAX) has been mixed between buying and selling, with 1 insider purchase totaling $4.80M and 34 insider sales totaling $9.07M. The most recent insider transaction was by Cohlhepp Ryan (director, officer: President and COO), who sold $253.6K worth of shares on May 18, 2026. Bicara Therapeutics Inc. Common Stock operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.26B.
BCAX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | Cohlhepp Ryan | director, officer: President and COO | Sell | 12,500 | $20.29 | $253.6K | 196,141 |
| Apr 28, 2026 | Raben David | officer: Chief Medical Officer | Sell | 5,500 | $22.88 | $125.8K | 55,286 |
| Apr 22, 2026 | Hyep Ivan | officer: Chief Financial Officer | Sell | 9,200 | $23.00 | $211.6K | 145,355 |
| Apr 20, 2026 | Mazumdar Claire | director, officer: Chief Executive Officer | Sell | 15,000 | $23.61 | $354.1K | 362,152 |
| Apr 17, 2026 | Cohlhepp Ryan | director, officer: President and COO | Sell | 12,500 | $23.01 | $287.6K | 200,641 |
| Mar 26, 2026 | Raben David | officer: Chief Medical Officer | Sell | 5,500 | $18.95 | $104.2K | 55,286 |
| Mar 24, 2026 | Hyep Ivan | officer: Chief Financial Officer | Sell | 9,200 | $18.52 | $170.3K | 145,355 |
| Mar 20, 2026 | Mazumdar Claire | director, officer: Chief Executive Officer | Sell | 15,000 | $18.82 | $282.4K | 339,392 |
| Mar 6, 2026 | Mazumdar Claire | director, officer: Chief Executive Officer | Sell | 8,234 | $18.74 | $154.3K | 339,392 |
| Mar 5, 2026 | Cohlhepp Ryan | director, officer: President and COO | Sell | 17,392 | $18.16 | $315.9K | 209,641 |
| Mar 5, 2026 | Hyep Ivan | officer: Chief Financial Officer | Sell | 16,518 | $18.22 | $301.0K | 145,355 |
| Mar 5, 2026 | Raben David | officer: Chief Medical Officer | Sell | 16,500 | $18.52 | $305.6K | 55,286 |
| Mar 2, 2026 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | Buy | 300,000 | $16.00 | $4.80M0.5% OS | 4,603,418 |
| Feb 27, 2026 | Cohlhepp Ryan | director, officer: President and COO | Sell | 3,631 | $18.04 | $65.5K | 210,164 |
| Jan 26, 2026 | Cohlhepp Ryan | director, officer: President and COO | Sell | 3,828 | $18.10 | $69.3K | 210,164 |
| Jan 26, 2026 | Hyep Ivan | officer: Chief Financial Officer | Sell | 1,882 | $18.15 | $34.2K | 145,355 |
| Jan 22, 2026 | Cohlhepp Ryan | President and COO | Sell | 3,828 | $18.10 | $69.3K | 0 |
| Jan 22, 2026 | Hyep Ivan | Chief Financial Officer | Sell | 1,882 | $18.15 | $34.2K | 0 |
| Jan 15, 2026 | Cohlhepp Ryan | President and COO | Sell | 149 | $18.02 | $2.7K | 0 |
| Dec 22, 2025 | Hyep Ivan | Chief Financial Officer | Sell | 9,200 | $18.31 | $168.5K | 0 |
| Dec 15, 2025 | Cohlhepp Ryan | President and COO | Sell | 12,500 | $18.68 | $233.5K | 0 |
| Nov 24, 2025 | Mazumdar Claire | Chief Executive Officer | Sell | 41,163 | $18.86 | $776.4K | 0 |
| Nov 24, 2025 | Raben David | Chief Medical Officer | Sell | 11,000 | $18.65 | $205.1K | 0 |
| Nov 21, 2025 | Cohlhepp Ryan | President and COO | Sell | 12,500 | $18.05 | $225.6K | 0 |
| Nov 21, 2025 | Hyep Ivan | Chief Financial Officer | Sell | 18,400 | $18.54 | $341.1K | 0 |
| Oct 16, 2025 | Mazumdar Claire | Chief Executive Officer | Sell | 24,103 | $18.83 | $453.8K | 0 |
| Oct 15, 2025 | Cohlhepp Ryan | President and COO | Sell | 12,500 | $18.16 | $226.9K | 0 |
| Oct 13, 2025 | Mazumdar Claire | Chief Executive Officer | Sell | 24,734 | $18.88 | $466.9K | 0 |
| Oct 9, 2025 | Hyep Ivan | Chief Financial Officer | Sell | 6,415 | $18.23 | $116.9K | 0 |
| Oct 9, 2025 | Raben David | Chief Medical Officer | Sell | 22,000 | $18.45 | $405.9K | 0 |
| Oct 6, 2025 | Cohlhepp Ryan | President and COO | Sell | 50,500 | $18.06 | $911.8K | 0 |
| Oct 6, 2025 | Hyep Ivan | Chief Financial Officer | Sell | 30,385 | $18.21 | $553.2K | 0 |
| Sep 29, 2025 | Meisner Lara | Chief Legal Officer | Sell | 33,807 | $14.75 | $498.7K | 0 |
| Sep 15, 2025 | Meisner Lara | Chief Legal Officer | Sell | 15,829 | $11.49 | $181.9K | 0 |
| Jun 16, 2025 | Meisner Lara | Chief Legal Officer | Sell | 15,829 | $10.43 | $165.1K | 0 |
| Mar 14, 2025 | Meisner Lara | Chief Legal Officer | Sell | 79,146 | $12.90 | $1.02M | 0 |
| Sep 17, 2024 | Flynn James E | 10% Owner | Buy | 35,000 | $18.00 | $630.0K | 0 |
BCAX Insider Buying Activity
The following table shows recent insider purchases of Bicara Therapeutics Inc. Common Stock (BCAX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | Buy | 300,000 | $16.00 | $4.80M0.5% OS | 4,603,418 |
| Sep 17, 2024 | Flynn James E | 10% Owner | Buy | 35,000 | $18.00 | $630.0K | 0 |
BCAX Insider Selling Activity
The following table shows recent insider sales of Bicara Therapeutics Inc. Common Stock (BCAX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | Cohlhepp Ryan | director, officer: President and COO | Sell | 12,500 | $20.29 | $253.6K | 196,141 |
| Apr 28, 2026 | Raben David | officer: Chief Medical Officer | Sell | 5,500 | $22.88 | $125.8K | 55,286 |
| Apr 22, 2026 | Hyep Ivan | officer: Chief Financial Officer | Sell | 9,200 | $23.00 | $211.6K | 145,355 |
| Apr 20, 2026 | Mazumdar Claire | director, officer: Chief Executive Officer | Sell | 15,000 | $23.61 | $354.1K | 362,152 |
| Apr 17, 2026 | Cohlhepp Ryan | director, officer: President and COO | Sell | 12,500 | $23.01 | $287.6K | 200,641 |
| Mar 26, 2026 | Raben David | officer: Chief Medical Officer | Sell | 5,500 | $18.95 | $104.2K | 55,286 |
| Mar 24, 2026 | Hyep Ivan | officer: Chief Financial Officer | Sell | 9,200 | $18.52 | $170.3K | 145,355 |
| Mar 20, 2026 | Mazumdar Claire | director, officer: Chief Executive Officer | Sell | 15,000 | $18.82 | $282.4K | 339,392 |
| Mar 6, 2026 | Mazumdar Claire | director, officer: Chief Executive Officer | Sell | 8,234 | $18.74 | $154.3K | 339,392 |
| Mar 5, 2026 | Cohlhepp Ryan | director, officer: President and COO | Sell | 17,392 | $18.16 | $315.9K | 209,641 |
| Mar 5, 2026 | Hyep Ivan | officer: Chief Financial Officer | Sell | 16,518 | $18.22 | $301.0K | 145,355 |
| Mar 5, 2026 | Raben David | officer: Chief Medical Officer | Sell | 16,500 | $18.52 | $305.6K | 55,286 |
| Feb 27, 2026 | Cohlhepp Ryan | director, officer: President and COO | Sell | 3,631 | $18.04 | $65.5K | 210,164 |
| Jan 26, 2026 | Cohlhepp Ryan | director, officer: President and COO | Sell | 3,828 | $18.10 | $69.3K | 210,164 |
| Jan 26, 2026 | Hyep Ivan | officer: Chief Financial Officer | Sell | 1,882 | $18.15 | $34.2K | 145,355 |
| Jan 22, 2026 | Cohlhepp Ryan | President and COO | Sell | 3,828 | $18.10 | $69.3K | 0 |
| Jan 22, 2026 | Hyep Ivan | Chief Financial Officer | Sell | 1,882 | $18.15 | $34.2K | 0 |
| Jan 15, 2026 | Cohlhepp Ryan | President and COO | Sell | 149 | $18.02 | $2.7K | 0 |
| Dec 22, 2025 | Hyep Ivan | Chief Financial Officer | Sell | 9,200 | $18.31 | $168.5K | 0 |
| Dec 15, 2025 | Cohlhepp Ryan | President and COO | Sell | 12,500 | $18.68 | $233.5K | 0 |
| Nov 24, 2025 | Mazumdar Claire | Chief Executive Officer | Sell | 41,163 | $18.86 | $776.4K | 0 |
| Nov 24, 2025 | Raben David | Chief Medical Officer | Sell | 11,000 | $18.65 | $205.1K | 0 |
| Nov 21, 2025 | Cohlhepp Ryan | President and COO | Sell | 12,500 | $18.05 | $225.6K | 0 |
| Nov 21, 2025 | Hyep Ivan | Chief Financial Officer | Sell | 18,400 | $18.54 | $341.1K | 0 |
| Oct 16, 2025 | Mazumdar Claire | Chief Executive Officer | Sell | 24,103 | $18.83 | $453.8K | 0 |
| Oct 15, 2025 | Cohlhepp Ryan | President and COO | Sell | 12,500 | $18.16 | $226.9K | 0 |
| Oct 13, 2025 | Mazumdar Claire | Chief Executive Officer | Sell | 24,734 | $18.88 | $466.9K | 0 |
| Oct 9, 2025 | Hyep Ivan | Chief Financial Officer | Sell | 6,415 | $18.23 | $116.9K | 0 |
| Oct 9, 2025 | Raben David | Chief Medical Officer | Sell | 22,000 | $18.45 | $405.9K | 0 |
| Oct 6, 2025 | Cohlhepp Ryan | President and COO | Sell | 50,500 | $18.06 | $911.8K | 0 |
| Oct 6, 2025 | Hyep Ivan | Chief Financial Officer | Sell | 30,385 | $18.21 | $553.2K | 0 |
| Sep 29, 2025 | Meisner Lara | Chief Legal Officer | Sell | 33,807 | $14.75 | $498.7K | 0 |
| Sep 15, 2025 | Meisner Lara | Chief Legal Officer | Sell | 15,829 | $11.49 | $181.9K | 0 |
| Jun 16, 2025 | Meisner Lara | Chief Legal Officer | Sell | 15,829 | $10.43 | $165.1K | 0 |
| Mar 14, 2025 | Meisner Lara | Chief Legal Officer | Sell | 79,146 | $12.90 | $1.02M | 0 |
BCAX Insiders
Similar Stocks to BCAX
VRTX
Vertex Pharmaceuticals Incorporated
$435.97-0.14%
$114.32B
REGN
Regeneron Pharmaceuticals, Inc.
$632.64+0.61%
$73.44B
ALNY
Alnylam Pharmaceuticals, Inc.
$293.79+2.64%
$39.18B
RVMD
Revolution Medicines, Inc.
$146.68+1.56%
$31.78B
INSM
Insmed Incorporated
$107.17+0.00%
$25.06B
UTHR
United Therapeutics Corporation
$565.60-0.30%
$24.13B
ROIV
Roivant Sciences Ltd.
$28.27-0.96%
$20.96B
MRNA
Moderna, Inc.
$45.97-4.45%
$19.46B